Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Breast Cancer Res Retrieve available abstracts of 174 articles: HTML format

Single Articles

March 2023
1. ROLLAND AL, Porro B, Kab S, Ribet C, et al
   Impact of breast cancer care pathways and related symptoms on the return-to-work process: results from a population-based French cohort study (CONSTANCES).
   Breast Cancer Res. 2023;25:30.
   PubMed     Abstract available
   
   
   
2. WANG W, Rana PS, Markovic V, Sossey-Alaoui K, et al
   The WAVE3/beta-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
   Breast Cancer Res. 2023;25:31.
   PubMed     Abstract available
   
   
   
3. GUNNARSDOTTIR FB, Bendahl PO, Johansson A, Benfeitas R, et al
   Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
   Breast Cancer Res. 2023;25:29.
   PubMed     Abstract available
   
   
   
4. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
   Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
   Breast Cancer Res. 2023;25:28.
   PubMed    
   
   
   
5. TUNALI G, Yanik H, Ozturk SC, Demirkol-Canli S, et al
   A positive feedback loop driven by fibronectin and IL-1beta sustains the inflammatory microenvironment in breast cancer.
   Breast Cancer Res. 2023;25:27.
   PubMed     Abstract available
   
   
   
6. PECAR G, Liu S, Hooda J, Atkinson JM, et al
   RET signaling in breast cancer therapeutic resistance and metastasis.
   Breast Cancer Res. 2023;25:26.
   PubMed     Abstract available
   
   
   
7. CHAUDHARY S, Appadurai MI, Maurya SK, Nallasamy P, et al
   MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
   Breast Cancer Res. 2023;25:25.
   PubMed     Abstract available
   
   
   
8. HATHAWAY CA, Rice MS, Collins LC, Chen D, et al
   Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
   Breast Cancer Res. 2023;25:24.
   PubMed     Abstract available
   
   
   February 2023
9. CHEN ZH, Tian Y, Zhou GL, Yue HR, et al
   CMTM7 inhibits breast cancer progression by regulating Wnt/beta-catenin signaling.
   Breast Cancer Res. 2023;25:22.
   PubMed     Abstract available
   
   
   
10. SAEKI S, Kumegawa K, Takahashi Y, Yang L, et al
    Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
    Breast Cancer Res. 2023;25:21.
    PubMed     Abstract available
    
    
    
11. LEE ES, Kim Y, Shin HC, Hwang KT, et al
    Diagnostic accuracy of a three-protein signature in women with suspicious breast lesions: a multicenter prospective trial.
    Breast Cancer Res. 2023;25:20.
    PubMed     Abstract available
    
    
    
12. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.
    Breast Cancer Res. 2023;25:18.
    PubMed     Abstract available
    
    
    
13. OUYANG D, Hong T, Fu M, Li Y, et al
    METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Breast Cancer Res. 2023;25:19.
    PubMed     Abstract available
    
    
    
14. CHOWDHURY A, Pharoah PD, Rueda OM
    Evaluation and comparison of different breast cancer prognosis scores based on gene expression data.
    Breast Cancer Res. 2023;25:17.
    PubMed     Abstract available
    
    
    
15. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Correction: Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:16.
    PubMed    
    
    
    
16. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    Correction: A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:15.
    PubMed    
    
    
    January 2023
17. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:13.
    PubMed     Abstract available
    
    
    
18. AYENI OA, Jofe M, Mapanga W, Chen WC, et al
    Correction: Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:14.
    PubMed    
    
    
    
19. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:12.
    PubMed     Abstract available
    
    
    
20. LIEN HC, Hsu CL, Lu YS, Chen TW, et al
    Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
    Breast Cancer Res. 2023;25:11.
    PubMed     Abstract available
    
    
    
21. LIU Z, Choksi S, Kwon HJ, Jiao D, et al
    Tumor necroptosis-mediated shedding of cell surface proteins promotes metastasis of breast cancer by suppressing anti-tumor immunity.
    Breast Cancer Res. 2023;25:10.
    PubMed     Abstract available
    
    
    
22. SCHONBERG MA, Wolfson EA, Eliassen AH, Bertrand KA, et al
    A model for predicting both breast cancer risk and non-breast cancer death among women > 55 years old.
    Breast Cancer Res. 2023;25:8.
    PubMed     Abstract available
    
    
    
23. WANG Y, Liu F, Sun L, Jia Y, et al
    Association between human blood metabolome and the risk of breast cancer.
    Breast Cancer Res. 2023;25:9.
    PubMed     Abstract available
    
    
    
24. AYENI OA, Joffe M, Mapanga W, Chen WC, et al
    Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:7.
    PubMed     Abstract available
    
    
    
25. TODHUNTER ME, Miyano M, Carlson EG, Hinz S, et al
    Sustained postconfluent culture of human mammary epithelial cells enriches for luminal and c-Kit+ subtypes.
    Breast Cancer Res. 2023;25:6.
    PubMed     Abstract available
    
    
    
26. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:5.
    PubMed     Abstract available
    
    
    
27. CAO Z, Liu R, Li Y, Luo X, et al
    MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer.
    Breast Cancer Res. 2023;25:3.
    PubMed     Abstract available
    
    
    
28. KIM CG, Kim MH, Kim JH, Kim SG, et al
    On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
    Breast Cancer Res. 2023;25:4.
    PubMed     Abstract available
    
    
    
29. DE HAAS SL, Slamon DJ, Martin M, Press MF, et al
    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    Breast Cancer Res. 2023;25:2.
    PubMed     Abstract available
    
    
    
30. CHEN S, Paul MR, Sterner CJ, Belka GK, et al
    PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
    Breast Cancer Res. 2023;25:1.
    PubMed     Abstract available
    
    
    December 2022
31. ANANDARAJAH A, Chen Y, Colditz GA, Hardi A, et al
    Studies of parenchymal texture added to mammographic breast density and risk of breast cancer: a systematic review of the methods used in the literature.
    Breast Cancer Res. 2022;24:101.
    PubMed     Abstract available
    
    
    
32. SHAH JS, Milevskiy MJG, Petrova V, Au AYM, et al
    Towards resolution of the intron retention paradox in breast cancer.
    Breast Cancer Res. 2022;24:100.
    PubMed     Abstract available
    
    
    
33. LUO J, Zou H, Guo Y, Tong T, et al
    SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
    Breast Cancer Res. 2022;24:99.
    PubMed     Abstract available
    
    
    
34. YADAV N, Sunder R, Desai S, Dharavath B, et al
    Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer.
    Breast Cancer Res. 2022;24:97.
    PubMed     Abstract available
    
    
    
35. JOE NS, Godet I, Milki N, Ain NUI, et al
    Mebendazole prevents distant organ metastases in part by decreasing ITGbeta4 expression and cancer stemness.
    Breast Cancer Res. 2022;24:98.
    PubMed     Abstract available
    
    
    
36. LEE ARGOV EJ, Rodriguez CB, Agovino M, Wei Y, et al
    Breast cancer worry, uncertainty, and perceived risk following breast density notification in a longitudinal mammography screening cohort.
    Breast Cancer Res. 2022;24:95.
    PubMed     Abstract available
    
    
    
37. KIM S, Tran TXM, Song H, Park B, et al
    Microcalcifications, mammographic breast density, and risk of breast cancer: a cohort study.
    Breast Cancer Res. 2022;24:96.
    PubMed     Abstract available
    
    
    
38. FERNANDEZ G, Prastawa M, Madduri AS, Scott R, et al
    Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years.
    Breast Cancer Res. 2022;24:93.
    PubMed     Abstract available
    
    
    
39. PAN Y, Yang Y, Huang R, Yang H, et al
    Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors.
    Breast Cancer Res. 2022;24:92.
    PubMed     Abstract available
    
    
    
40. SIRVEN P, Faucheux L, Grandclaudon M, Michea P, et al
    Definition of a novel breast tumor-specific classifier based on secretome analysis.
    Breast Cancer Res. 2022;24:94.
    PubMed     Abstract available
    
    
    
41. DORGAN JF, Baer HJ, Bertrand KA, LeBlanc ES, et al
    Childhood adiposity, serum metabolites and breast density in young women.
    Breast Cancer Res. 2022;24:91.
    PubMed     Abstract available
    
    
    
42. SGROI DC, Treuner K, Zhang Y, Piper T, et al
    Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Breast Cancer Res. 2022;24:90.
    PubMed     Abstract available
    
    
    
43. YAGHJYAN L, Eliassen AH, Colditz G, Rosner B, et al
    Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
    Breast Cancer Res. 2022;24:89.
    PubMed     Abstract available
    
    
    
44. SEMINA SE, Alejo LH, Chopra S, Kansara NS, et al
    Identification of a novel ER-NFkB-driven stem-like cell population associated with relapse of ER+ breast tumors.
    Breast Cancer Res. 2022;24:88.
    PubMed     Abstract available
    
    
    
45. HASSAINE Y, Jacquet E, Seigneurin A, Delafosse P, et al
    Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?
    Breast Cancer Res. 2022;24:87.
    PubMed     Abstract available
    
    
    
46. DAVIS LYNN BC, Lord BD, Cora R, Pfeiffer RM, et al
    Associations between quantitative measures of TDLU involution and breast tumor molecular subtypes among breast cancer cases in the Black Women's Health Study: a case-case analysis.
    Breast Cancer Res. 2022;24:86.
    PubMed     Abstract available
    
    
    November 2022
47. GU J, Ternifi R, Sabeti S, Larson NB, et al
    Volumetric imaging and morphometric analysis of breast tumor angiogenesis using a new contrast-free ultrasound technique: a feasibility study.
    Breast Cancer Res. 2022;24:85.
    PubMed     Abstract available
    
    
    
48. PHILIPPSON C, Larsen S, Simon S, Vandekerkhove C, et al
    Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.
    Breast Cancer Res. 2022;24:83.
    PubMed     Abstract available
    
    
    
49. BALLINGER TJ, Thompson WR, Guise TA
    The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health.
    Breast Cancer Res. 2022;24:84.
    PubMed     Abstract available
    
    
    
50. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:82.
    PubMed    
    
    
    
51. WU L, Ye W, Liu Y, Chen D, et al
    An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study.
    Breast Cancer Res. 2022;24:81.
    PubMed     Abstract available
    
    
    
52. BALLOT E, Galland L, Mananet H, Boidot R, et al
    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Breast Cancer Res. 2022;24:80.
    PubMed     Abstract available
    
    
    
53. KOLYVAS EA, Caldas C, Kelly K, Ahmad SS, et al
    Androgen receptor function and targeted therapeutics across breast cancer subtypes.
    Breast Cancer Res. 2022;24:79.
    PubMed     Abstract available
    
    
    
54. ASAD S, Damicis A, Heng YJ, Kananen K, et al
    Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
    Breast Cancer Res. 2022;24:78.
    PubMed     Abstract available
    
    
    
55. PEDERSEN DC, Jensen BW, Tjonneland A, Andersen ZJ, et al
    Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes.
    Breast Cancer Res. 2022;24:77.
    PubMed     Abstract available
    
    
    
56. SZABOVA L, Gordon MB, Lu L, Pate N, et al
    Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Breast Cancer Res. 2022;24:75.
    PubMed     Abstract available
    
    
    
57. CRAGER M, Wijayawardana SR, Gruver AM, Blacklock A, et al
    Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score(R) result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
    Breast Cancer Res. 2022;24:74.
    PubMed     Abstract available
    
    
    October 2022
58. HAN SJ, Sung N, Wang J, O'Malley BW, et al
    Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
    Breast Cancer Res. 2022;24:73.
    PubMed     Abstract available
    
    
    
59. KARTHIKEYAN S, Casey PJ, Wang M
    RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation.
    Breast Cancer Res. 2022;24:72.
    PubMed     Abstract available
    
    
    
60. LA VERDE N, Damia G, Garrone O, Santini D, et al
    Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
    Breast Cancer Res. 2022;24:71.
    PubMed     Abstract available
    
    
    
61. DU T, Pan L, Zheng C, Chen K, et al
    Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
    Breast Cancer Res. 2022;24:70.
    PubMed     Abstract available
    
    
    
62. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:69.
    PubMed     Abstract available
    
    
    
63. ZHENG ZY, Elsarraj H, Lei JT, Hong Y, et al
    Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Breast Cancer Res. 2022;24:68.
    PubMed     Abstract available
    
    
    
64. ONAGI H, Horimoto Y, Sakaguchi A, Ikarashi D, et al
    High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
    Breast Cancer Res. 2022;24:67.
    PubMed     Abstract available
    
    
    
65. NOUNU A, Kar SP, Relton CL, Richmond RC, et al
    Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
    Breast Cancer Res. 2022;24:66.
    PubMed     Abstract available
    
    
    
66. LUCHTENBORG AM, Metzger P, Cosenza Contreras M, Oria V, et al
    Kruppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.
    Breast Cancer Res. 2022;24:65.
    PubMed     Abstract available
    
    
    September 2022
67. ZIOLKOWSKI P, Wozniak M, Mansour A, An Y, et al
    Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis.
    Breast Cancer Res. 2022;24:64.
    PubMed     Abstract available
    
    
    
68. DENG N, Minoche A, Harvey K, Li M, et al
    Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models.
    Breast Cancer Res. 2022;24:63.
    PubMed     Abstract available
    
    
    
69. LOPEZ-KNOWLES E, Detre S, Hills M, Schuster EF, et al
    Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Breast Cancer Res. 2022;24:61.
    PubMed     Abstract available
    
    
    
70. LI C, Yoshimura T, Tian M, Wang Y, et al
    Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer.
    Breast Cancer Res. 2022;24:60.
    PubMed     Abstract available
    
    
    
71. LOUDIG O, Mitchell MI, Ben-Dov IZ, Liu C, et al
    MiRNA expression deregulation correlates with the Oncotype DX((R)) DCIS score.
    Breast Cancer Res. 2022;24:62.
    PubMed     Abstract available
    
    
    
72. DUGUE PA, Bodelon C, Chung FF, Brewer HR, et al
    Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.
    Breast Cancer Res. 2022;24:59.
    PubMed     Abstract available
    
    
    
73. KOLBERG-LIEDTKE C, Feuerhake F, Garke M, Christgen M, et al
    Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Breast Cancer Res. 2022;24:58.
    PubMed     Abstract available
    
    
    August 2022
74. LIU C, Hu S, Xu X, Zhang Y, et al
    Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment.
    Breast Cancer Res. 2022;24:57.
    PubMed     Abstract available
    
    
    
75. CLARKE S, Chin SN, Dodds L, George SHL, et al
    Racial disparities in breast cancer preclinical and clinical models.
    Breast Cancer Res. 2022;24:56.
    PubMed     Abstract available
    
    
    July 2022
76. JONES LI, Marshall A, Elangovan P, Geach R, et al
    Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset.
    Breast Cancer Res. 2022;24:55.
    PubMed     Abstract available
    
    
    
77. LEE S, Osmanbeyoglu HU
    Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
    Breast Cancer Res. 2022;24:54.
    PubMed     Abstract available
    
    
    
78. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2022;24:53.
    PubMed    
    
    
    
79. HANNA A, Nixon MJ, Estrada MV, Sanchez V, et al
    Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Breast Cancer Res. 2022;24:51.
    PubMed     Abstract available
    
    
    
80. SALVATI A, Melone V, Sellitto A, Rizzo F, et al
    Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Breast Cancer Res. 2022;24:52.
    PubMed     Abstract available
    
    
    
81. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2022;24:50.
    PubMed    
    
    
    
82. WARD SV, Burton A, Tamimi RM, Pereira A, et al
    The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density.
    Breast Cancer Res. 2022;24:49.
    PubMed     Abstract available
    
    
    
83. MIR S, Golden BDO, Griess BJ, Vengoji R, et al
    Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
    Breast Cancer Res. 2022;24:48.
    PubMed     Abstract available
    
    
    
84. AL-TWEIGERI T, AlRaouji NN, Tulbah A, Arafah M, et al
    High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients.
    Breast Cancer Res. 2022;24:46.
    PubMed     Abstract available
    
    
    
85. KEHM RD, Walter EJ, Oskar S, White ML, et al
    Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study.
    Breast Cancer Res. 2022;24:47.
    PubMed     Abstract available
    
    
    
86. OGONY J, de Bel T, Radisky DC, Kachergus J, et al
    Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.
    Breast Cancer Res. 2022;24:45.
    PubMed     Abstract available
    
    
    June 2022
87. WAGNER KU
    Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.
    Breast Cancer Res. 2022;24:44.
    PubMed    
    
    
    
88. PEDERSEN CA, Cao MD, Fleischer T, Rye MB, et al
    DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Breast Cancer Res. 2022;24:43.
    PubMed     Abstract available
    
    
    
89. WELLBERG EA, Corleto KA, Checkley LA, Jindal S, et al
    Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
    Breast Cancer Res. 2022;24:42.
    PubMed     Abstract available
    
    
    
90. RATZ L, Brambillasca C, Bartke L, Huetzen MA, et al
    Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Breast Cancer Res. 2022;24:41.
    PubMed     Abstract available
    
    
    
91. CARR D, Zein A, Coulombe J, Jiang T, et al
    Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.
    Breast Cancer Res. 2022;24:40.
    PubMed     Abstract available
    
    
    
92. ONG CHC, Lee DY, Lee B, Li H, et al
    Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Breast Cancer Res. 2022;24:38.
    PubMed     Abstract available
    
    
    
93. HARRASSER M, Gohil SH, Lau H, Della Peruta M, et al
    Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Breast Cancer Res. 2022;24:39.
    PubMed     Abstract available
    
    
    
94. SIEGEL SD, Brooks MM, Lynch SM, Sims-Mourtada J, et al
    Racial disparities in triple negative breast cancer: toward a causal architecture approach.
    Breast Cancer Res. 2022;24:37.
    PubMed     Abstract available
    
    
    May 2022
95. KOEVOETS EW, Schagen SB, de Ruiter MB, Geerlings MI, et al
    Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
    Breast Cancer Res. 2022;24:36.
    PubMed     Abstract available
    
    
    
96. RAGHAVAKAIMAL A, Cristofanilli M, Tang CM, Alpaugh RK, et al
    CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.
    Breast Cancer Res. 2022;24:35.
    PubMed     Abstract available
    
    
    
97. RALLI GP, Carter RD, McGowan DR, Cheng WC, et al
    Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.
    Breast Cancer Res. 2022;24:34.
    PubMed     Abstract available
    
    
    
98. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
    Breast Cancer Res. 2022;24:29.
    PubMed     Abstract available
    
    
    
99. ROUSSEAU B, Murugan S, Palagani A, Sarkar DK, et al
    Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.
    Breast Cancer Res. 2022;24:33.
    PubMed     Abstract available
    
    
    
100. ZHENG J, Zhang B
     Biological interpretation of prognostic radiomic score by correlating with tumor heterogeneity and microenvironment.
     Breast Cancer Res. 2022;24:32.
     PubMed    
     
     
     
101. HO WJ, Law AMK, Masle-Farquhar E, Castillo LE, et al
     Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.
     Breast Cancer Res. 2022;24:31.
     PubMed     Abstract available
     
     
     April 2022
102. GRINMAN DY, Boras-Granic K, Takyar FM, Dann P, et al
     PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.
     Breast Cancer Res. 2022;24:30.
     PubMed     Abstract available
     
     
     
103. MINTZ R, Wang M, Xu S, Colditz GA, et al
     Hormone and receptor activator of NF-kappaB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.
     Breast Cancer Res. 2022;24:28.
     PubMed     Abstract available
     
     
     
104. CHEN H, Fan S, Stone J, Thompson DJ, et al
     Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.
     Breast Cancer Res. 2022;24:27.
     PubMed     Abstract available
     
     
     
105. LIU Z, Liu J, Ebrahimi B, Pratap UP, et al
     SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
     Breast Cancer Res. 2022;24:26.
     PubMed     Abstract available
     
     
     
106. FOO SL, Sachaphibulkij K, Lee CLY, Yap GLR, et al
     Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1/formyl peptide receptor signaling.
     Breast Cancer Res. 2022;24:25.
     PubMed     Abstract available
     
     
     
107. RENAULT AL, Dowty JG, Steen JA, Li S, et al
     Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
     Breast Cancer Res. 2022;24:24.
     PubMed     Abstract available
     
     
     
108. HEYNEN GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, et al
     Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
     Breast Cancer Res. 2022;24:23.
     PubMed     Abstract available
     
     
     March 2022
109. WON HS, Ahn J, Kim Y, Kim JS, et al
     Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
     Breast Cancer Res. 2022;24:22.
     PubMed     Abstract available
     
     
     
110. TU CF, Li FA, Li LH, Yang RB, et al
     Quantitative glycoproteomics analysis identifies novel FUT8 targets and signaling networks critical for breast cancer cell invasiveness.
     Breast Cancer Res. 2022;24:21.
     PubMed     Abstract available
     
     
     
111. WANG X, Xie T, Luo J, Zhou Z, et al
     Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment.
     Breast Cancer Res. 2022;24:20.
     PubMed     Abstract available
     
     
     
112. SEMINA SE, Pal P, Kansara NS, Huggins RJ, et al
     Selective pressure of endocrine therapy activates the integrated stress response through NFkappaB signaling in a subpopulation of ER positive breast cancer cells.
     Breast Cancer Res. 2022;24:19.
     PubMed     Abstract available
     
     
     
113. LIU M, Smith R, Liby T, Chiotti K, et al
     INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
     Breast Cancer Res. 2022;24:18.
     PubMed     Abstract available
     
     
     
114. WATT AC, Goel S
     Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer.
     Breast Cancer Res. 2022;24:17.
     PubMed     Abstract available
     
     
     
115. GU J, Ternifi R, Larson NB, Carter JM, et al
     Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization.
     Breast Cancer Res. 2022;24:16.
     PubMed     Abstract available
     
     
     February 2022
116. SYRIOPOULOU E, Gasparini A, Humphreys K, Andersson TM, et al
     Assessing lead time bias due to mammography screening on estimates of loss in life expectancy.
     Breast Cancer Res. 2022;24:15.
     PubMed     Abstract available
     
     
     
117. GASTOUNIOTI A, Desai S, Ahluwalia VS, Conant EF, et al
     Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review.
     Breast Cancer Res. 2022;24:14.
     PubMed     Abstract available
     
     
     
118. THOMPSON KN, Ju JA, Ory EC, Pratt SJP, et al
     Microtubule disruption reduces metastasis more effectively than primary tumor growth.
     Breast Cancer Res. 2022;24:13.
     PubMed     Abstract available
     
     
     
119. SUN L, Ding H, Jia Y, Shi M, et al
     Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
     Breast Cancer Res. 2022;24:12.
     PubMed     Abstract available
     
     
     
120. WEI G, Teng M, Rosa M, Wang X, et al
     Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
     Breast Cancer Res. 2022;24:11.
     PubMed     Abstract available
     
     
     January 2022
121. REN Q, Khoo WH, Corr AP, Phan TG, et al
     Gene expression predicts dormant metastatic breast cancer cell phenotype.
     Breast Cancer Res. 2022;24:10.
     PubMed     Abstract available
     
     
     
122. GECZIK AM, Falk RT, Xu X, Ansong D, et al
     Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study.
     Breast Cancer Res. 2022;24:9.
     PubMed     Abstract available
     
     
     
123. TANG YH, Rockstroh A, Sokolowski KA, Lynam LR, et al
     Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
     Breast Cancer Res. 2022;24:8.
     PubMed     Abstract available
     
     
     
124. YIN L, Li Q, Mrdenovic S, Chu GC, et al
     KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.
     Breast Cancer Res. 2022;24:7.
     PubMed     Abstract available
     
     
     
125. DESHPANDE RP, Sharma S, Liu Y, Pandey PR, et al
     LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
     Breast Cancer Res. 2022;24:6.
     PubMed     Abstract available
     
     
     
126. PIRIKAHU S, Lund H, Cadby G, Wylie E, et al
     The impact of breast density notification on rescreening rates within a population-based mammographic screening program.
     Breast Cancer Res. 2022;24:5.
     PubMed     Abstract available
     
     
     
127. HJERKIND KV, Johansson ALV, Trewin CB, Russnes HG, et al
     Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway.
     Breast Cancer Res. 2022;24:4.
     PubMed     Abstract available
     
     
     
128. YOON L, Corvalan C, Pereira A, Shepherd J, et al
     Sugar-sweetened beverage consumption and breast composition in a longitudinal study of Chilean girls.
     Breast Cancer Res. 2022;24:3.
     PubMed     Abstract available
     
     
     
129. MENG L, Chang S, Sang Y, Ding P, et al
     Circular RNA circCCDC85A inhibits breast cancer progression via acting as a miR-550a-5p sponge to enhance MOB1A expression.
     Breast Cancer Res. 2022;24:1.
     PubMed     Abstract available
     
     
     
130. AHEARN TU, Zhang H, Michailidou K, Milne RL, et al
     Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
     Breast Cancer Res. 2022;24:2.
     PubMed     Abstract available
     
     
     December 2021
131. NIWINSKA A, Olszewski WP
     The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
     Breast Cancer Res. 2021;23:118.
     PubMed     Abstract available
     
     
     
132. SANDSVEDEN M, Borgquist S, Rosendahl AH, Manjer J, et al
     Low thyroid hormone receptor alpha-2 (THRalpha-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.
     Breast Cancer Res. 2021;23:117.
     PubMed     Abstract available
     
     
     
133. CHEUNG AM, Wang D, Liu K, Hope T, et al
     Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.
     Breast Cancer Res. 2021;23:114.
     PubMed     Abstract available
     
     
     
134. ZHANG M, Meng M, Liu Y, Qi J, et al
     Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
     Breast Cancer Res. 2021;23:116.
     PubMed     Abstract available
     
     
     
135. LIU S, Chen W, Hu H, Zhang T, et al
     Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
     Breast Cancer Res. 2021;23:115.
     PubMed     Abstract available
     
     
     
136. YAGHOOBI V, Moutafi M, Aung TN, Pelekanou V, et al
     Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
     Breast Cancer Res. 2021;23:113.
     PubMed     Abstract available
     
     
     
137. GAMPENRIEDER SP, Rinnerthaler G, Tinchon C, Petzer A, et al
     Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
     Breast Cancer Res. 2021;23:112.
     PubMed     Abstract available
     
     
     
138. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
     Early-life exposures and age at thelarche in the Sister Study cohort.
     Breast Cancer Res. 2021;23:111.
     PubMed     Abstract available
     
     
     November 2021
139. VIROSTKO J, Sorace AG, Slavkova KP, Kazerouni AS, et al
     Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting.
     Breast Cancer Res. 2021;23:110.
     PubMed     Abstract available
     
     
     
140. BOUCHERON P, Anele A, Zietsman A, Galukande M, et al
     Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study.
     Breast Cancer Res. 2021;23:109.
     PubMed     Abstract available
     
     
     
141. LABRECHE C, Cook DP, Abou-Hamad J, Pascoal J, et al
     Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFbeta/PI3K/AKT pathways.
     Breast Cancer Res. 2021;23:107.
     PubMed     Abstract available
     
     
     
142. BARBER LE, Zirpoli GR, Cozier YC, Rosenberg L, et al
     Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women.
     Breast Cancer Res. 2021;23:108.
     PubMed     Abstract available
     
     
     
143. LIU FC, Veierod MB, Kjaerheim K, Robsahm TE, et al
     Excess risk of male breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a possible link to extreme night shift work?
     Breast Cancer Res. 2021;23:106.
     PubMed    
     
     
     
144. BODELON C, Mullooly M, Pfeiffer RM, Fan S, et al
     Mammary collagen architecture and its association with mammographic density and lesion severity among women undergoing image-guided breast biopsy.
     Breast Cancer Res. 2021;23:105.
     PubMed     Abstract available
     
     
     
145. JESSER EA, Brady NJ, Huggins DN, Witschen PM, et al
     STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment.
     Breast Cancer Res. 2021;23:104.
     PubMed     Abstract available
     
     
     
146. HANAMURA T, Christenson JL, O'Neill KI, Rosas E, et al
     Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
     Breast Cancer Res. 2021;23:102.
     PubMed     Abstract available
     
     
     
147. COLLIN LJ, Maliniak ML, Cronin-Fenton DP, Ahern TP, et al
     Hypoxia-inducible factor-1alpha expression and breast cancer recurrence in a Danish population-based case control study.
     Breast Cancer Res. 2021;23:103.
     PubMed     Abstract available
     
     
     October 2021
148. ROPRI AS, DeVaux RS, Eng J, Chittur SV, et al
     Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
     Breast Cancer Res. 2021;23:101.
     PubMed     Abstract available
     
     
     
149. SCHERER SD, Riggio AI, Haroun F, DeRose YS, et al
     An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
     Breast Cancer Res. 2021;23:100.
     PubMed     Abstract available
     
     
     
150. SAKAGUCHI A, Horimoto Y, Onagi H, Ikarashi D, et al
     Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
     Breast Cancer Res. 2021;23:99.
     PubMed     Abstract available
     
     
     
151. FUH KF, Shepherd RD, Withell JS, Kooistra BK, et al
     Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.
     Breast Cancer Res. 2021;23:97.
     PubMed     Abstract available
     
     
     
152. CHEN X, Chen DG, Zhao Z, Balko JM, et al
     Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.
     Breast Cancer Res. 2021;23:96.
     PubMed     Abstract available
     
     
     
153. HAZLETT J, Niemi V, Aiderus A, Powell K, et al
     Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.
     Breast Cancer Res. 2021;23:95.
     PubMed     Abstract available
     
     
     September 2021
154. LIOU L, Kaptoge S, Dennis J, Shah M, et al
     Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
     Breast Cancer Res. 2021;23:94.
     PubMed     Abstract available
     
     
     
155. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
     Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
     Breast Cancer Res. 2021;23:91.
     PubMed     Abstract available
     
     
     
156. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
     Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
     Breast Cancer Res. 2021;23:93.
     PubMed     Abstract available
     
     
     
157. ZARE A, Postovit LM, Githaka JM
     Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
     Breast Cancer Res. 2021;23:92.
     PubMed     Abstract available
     
     
     
158. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
     A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
     Breast Cancer Res. 2021;23:90.
     PubMed     Abstract available
     
     
     
159. YANG L, Wang B, Jiao X, Zhou C, et al
     TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
     Breast Cancer Res. 2021;23:89.
     PubMed     Abstract available
     
     
     July 2021
160. HIS M, Lajous M, Gomez-Flores-Ramos L, Monge A, et al
     Biomarkers of mammographic density in premenopausal women.
     Breast Cancer Res. 2021;23:75.
     PubMed     Abstract available
     
     
     
161. LU P, Foley J, Zhu C, McNamara K, et al
     Transcriptome and genome evolution during HER2-amplified breast neoplasia.
     Breast Cancer Res. 2021;23:73.
     PubMed     Abstract available
     
     
     
162. GARZIA NA, Cushing-Haugen K, Kensler TW, Tamimi RM, et al
     Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density.
     Breast Cancer Res. 2021;23:71.
     PubMed     Abstract available
     
     
     June 2021
163. RUTH JR, Pant DK, Pan TC, Seidel HE, et al
     Cellular dormancy in minimal residual disease following targeted therapy.
     Breast Cancer Res. 2021;23:63.
     PubMed     Abstract available
     
     
     May 2021
164. SARRADIN V, Lusque A, Filleron T, Dalenc F, et al
     Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
     Breast Cancer Res. 2021;23:61.
     PubMed     Abstract available
     
     
     
165. DE BOER LL, Kho E, Van de Vijver KK, Vranken Peeters MTFD, et al
     Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance.
     Breast Cancer Res. 2021;23:59.
     PubMed     Abstract available
     
     
     
166. CONG L, Maishi N, Annan DA, Young MF, et al
     Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
     Breast Cancer Res. 2021;23:51.
     PubMed     Abstract available
     
     
     April 2021
167. REIMERS LL, Goldberg M, Tehranifar P, Michels KB, et al
     Benign breast disease and changes in mammographic breast density.
     Breast Cancer Res. 2021;23:49.
     PubMed     Abstract available
     
     
     
168. YANG HY, Tu CW, Chen CC, Lee CY, et al
     Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience.
     Breast Cancer Res. 2021;23:43.
     PubMed     Abstract available
     
     
     February 2021
169. SZUCS Z, Joseph J, Larkin TJ, Xie B, et al
     Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
     Breast Cancer Res. 2021;23:25.
     PubMed     Abstract available
     
     
     
170. TIAN J, Wang V, Wang N, Khadang B, et al
     Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
     Breast Cancer Res. 2021;23:23.
     PubMed     Abstract available
     
     
     January 2021
171. ALTOE ML, Kalinsky K, Marone A, Kim HK, et al
     Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
     Breast Cancer Res. 2021;23:16.
     PubMed     Abstract available
     
     
     
172. BAI F, Liu S, Liu X, Hollern DP, et al
     PDGFRbeta is an essential therapeutic target for BRCA1-deficient mammary tumors.
     Breast Cancer Res. 2021;23:10.
     PubMed     Abstract available
     
     
     
173. RIEDLINGER GM, Joshi S, Hirshfield KM, Barnard N, et al
     Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
     Breast Cancer Res. 2021;23:7.
     PubMed     Abstract available
     
     
     
174. MCCART REED AE, Kalinowski L, Simpson PT, Lakhani SR, et al
     Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
     Breast Cancer Res. 2021;23:6.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: